{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:05:28Z","timestamp":1771977928841,"version":"3.50.1"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Little is known on the mechanisms of tolerance to factor VIII (FVIII) in haemophilia A (HA) patients. To identify immunological markers in tolerance development, samples from two patients with HA treated with rFVIIIFc after a history of inhibitors were analyzed. The patients have been followed closely during re-exposure with FVIII as part of immune tolerance induction. Plasma samples were analyzed for FVIII inhibitors and FVIII-specific antibodies. Analysis of further immunological markers was performed for patient 2 using peripheral blood mononuclear cells (PBMCs); additionally, cytokines in cell culture media were quantified. Laboratory data were compared to pharmacological parameters and clinical outcome.<\/jats:p>\n                  <jats:p>Both patients showed a decline in FVIII recovery (exposure day [ED] 12 for patient 1, ED 25 for patient 2). During that time patient 2 was positive for lupus anticoagulants and a low amount of FVIII-specific antibodies was detectable in ELISA. However, specificity could not be verified by competition and antibodies disappeared again after ED 25. Patient 1 developed FVIII-specific antibodies of subclass IgG4 after ED 229. Antibodies were mainly directed against the FVIII light chain. FVIII-responsive CD4+ T-cells were detectable in the patient's PBMCs. Additionally, PMBCs showed an elevated production of IL-23 and TNF-\u03b1 when stimulated with FVIII.<\/jats:p>\n                  <jats:p>A prospective analysis of the described parameters might help to identify the onset of an immune response. Even though the number of analyzed patients is low, the detailed analyses may help to further understand the development of tolerance to FVIII and to define starting points for further interventions against treatment complications through inhibitor development in HA.<\/jats:p>","DOI":"10.1055\/a-2722-8734","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:50:47Z","timestamp":1771977047000},"source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Soluble and Humoral Immunological Parameters During Re-exposure with rFVIIIFc after History of Inhibitors"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8565-3964","authenticated-orcid":false,"given":"Anja","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, Frankfurt am Main, Germany Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schultze-Strasser","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, Frankfurt am Main, Germany Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Stichel","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, Frankfurt am Main, Germany Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Orlowski","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, Frankfurt am Main, Germany Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Heller","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, Frankfurt am Main, Germany Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-2439","authenticated-orcid":false,"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt, University Hospital, Department of Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, Frankfurt am Main, Germany Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"A Cannav\u00f2","year":"2017","journal-title":"Blood"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.2022016530","article-title":"Immune complications and their management in inherited and acquired bleeding disorders","volume":"140","author":"V R Arruda","year":"2022","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1019275","DOI":"10.3389\/fimmu.2022.1019275","article-title":"Hemophilia a patients with inhibitors: mechanistic insights and novel therapeutic implications","volume":"13","author":"L Luo","year":"2022","journal-title":"Front Immunol"},{"issue":"S 06","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-020-01511-8","article-title":"European principles of inhibitor management in patients with haemophilia: implications of new treatment options","volume":"15","author":"C Hermans","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"S 05","key":"ref6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/hae.12989","article-title":"Innovating immune tolerance induction for haemophilia","volume":"22","author":"G Batsuli","year":"2016","journal-title":"Haemophilia"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2016.10.015","article-title":"Current view and outcome of ITI therapy\u2014a change over time?","volume":"148","author":"K Holstein","year":"2016","journal-title":"Thromb Res"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jth.12768","article-title":"Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay","volume":"13","author":"B Boylan","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2016-11-751347","article-title":"Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A","volume":"130","author":"J Kahle","year":"2017","journal-title":"Blood"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood.V104.11.3081.3081","article-title":"Epitope mapping during FVIII inhibitor elimination with rituximab revealed conformational epitopes on FVIII and identifies potentially small molecules for novel therapies","volume":"104","author":"C K\u00f6nigs","year":"2004","journal-title":"Blood"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1160\/TH03-07-0473","article-title":"Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display","volume":"91","author":"C M\u00fchle","year":"2004","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref12","first-page":"522","article-title":"Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site","volume":"92","author":"K P Pratt","year":"2004","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-06-1886","article-title":"Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor","volume":"102","author":"S Villard","year":"2003","journal-title":"Blood"},{"issue":"13","key":"ref14","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"J Astermark","year":"2015","journal-title":"Blood"},{"issue":"S 02","key":"ref15","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1055\/s-0037-1616867","article-title":"Regulatory T cells and their potential for tolerance induction in haemophilia A patients","volume":"36","author":"A Schmidt","year":"2016","journal-title":"Hamostaseologie"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2022008071","article-title":"Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01\/2010 study","volume":"7","author":"O Oleshko","year":"2023","journal-title":"Blood Adv"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molimm.2008.06.015","article-title":"Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab","volume":"46","author":"C Kessel","year":"2008","journal-title":"Mol Immunol"},{"issue":"03","key":"ref19","first-page":"290","article-title":"Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells","volume":"142","author":"R Kaczmarek","year":"2023","journal-title":"Blood"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/jha2.319","article-title":"CD4+ regulatory and na\u00efve T cells specific for factor VIII stand vis-\u00e0-vis to balance the immune response in healthy individuals","volume":"2","author":"A Schmidt","year":"2021","journal-title":"eJHaem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207241300809","article-title":"Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses","volume":"15","author":"C K\u00f6nigs","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"975680","DOI":"10.3389\/fimmu.2022.975680","article-title":"Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells","volume":"13","author":"C Lubich","year":"2022","journal-title":"Front Immunol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12878-014-0019-8","article-title":"The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors","volume":"15","author":"A C Silveira","year":"2015","journal-title":"BMC Hematol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/hae.14885","article-title":"Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies","volume":"30","author":"J M\u00fcller","year":"2024","journal-title":"Haemophilia"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.2196\/resprot.6558","article-title":"Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"A Iorio","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"05","key":"ref26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1055\/a-2329-1781","article-title":"Acid treatment of FVIII-containing plasma samples unmasks a broad spectrum of FVIII-specific antibodies in ELISA","volume":"44","author":"A Schmidt","year":"2024","journal-title":"Hamostaseologie"},{"issue":"S 01","key":"ref27","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1055\/s-0037-1619801","article-title":"Selection and characterisation of FVIII-specific single chain variable fragments","volume":"33","author":"A Naumann","year":"2013","journal-title":"Hamostaseologie"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.4049\/jimmunol.1201090","article-title":"A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg","volume":"189","author":"A Schoenbrunn","year":"2012","journal-title":"J Immunol"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1111\/hae.12956","article-title":"Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B","volume":"22","author":"A Barnbrock","year":"2016","journal-title":"Haemophilia"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/hae.13565","article-title":"Distinguishing lupus anticoagulants from factor VIII inhibitors in haemophilic and non-haemophilic patients","volume":"24","author":"A G Rampersad","year":"2018","journal-title":"Haemophilia"},{"issue":"16","key":"ref31","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.2022017780","article-title":"Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study","volume":"141","author":"L Malec","year":"2023","journal-title":"Blood"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/hae.13413","article-title":"Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors\u2014a retrospective analysis","volume":"24","author":"M Carcao","year":"2018","journal-title":"Haemophilia"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/hae.13105","article-title":"Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics","volume":"23","author":"J Kahle","year":"2017","journal-title":"Haemophilia"},{"issue":"21","key":"ref34","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/bloodadvances.2017008706","article-title":"CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na\u00efve and memory cells","volume":"1","author":"S Meunier","year":"2017","journal-title":"Blood Adv"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1538-7836.2011.04267.x","article-title":"Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells","volume":"9","author":"B Pautard","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1600-6143.2008.02459.x","article-title":"Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation","volume":"9","author":"C Ashokkumar","year":"2009","journal-title":"Am J Transplant"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/bloodadvances.2021005745","article-title":"Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors","volume":"6","author":"H Schweiger","year":"2022","journal-title":"Blood Adv"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12185-022-03359-z","article-title":"Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy","volume":"116","author":"T Yoshimura","year":"2022","journal-title":"Int J Hematol"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1160\/TH17-01-0059","article-title":"Risk factors for the progression from low to high titres in 260 children with severe haemophilia A and newly developed inhibitors","volume":"117","author":"M E Mancuso","year":"2017","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2141.2008.07232.x","article-title":"IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A","volume":"142","author":"P MW van Helden","year":"2008","journal-title":"Br J Haematol"},{"issue":"22","key":"ref41","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"B M Reipert","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"ref42","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","article-title":"Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A","volume":"108","author":"J Astermark","year":"2006","journal-title":"Blood"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2722-8734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:51:05Z","timestamp":1771977065000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2722-8734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1055\/a-2722-8734","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}